IV 
112TH CONGRESS 
2D SESSION 
H. RES. 594 
Commending the progress made by anti-tuberculosis programs. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 22, 2012 
Mr. ENGEL (for himself, Mr. GENE GREEN of Texas, Mr. YOUNG of Alaska, 
Ms. LEE of California, Mr. GRIJALVA, Mr. TOWNS, Mr. COHEN, Mr. 
SMITH of Washington, Ms. SCHAKOWSKY, and Mrs. MALONEY) submitted 
the following resolution; which was referred to the Committee on Foreign 
Affairs, and in addition to the Committee on Energy and Commerce, for 
a period to be subsequently determined by the Speaker, in each case for 
consideration of such provisions as fall within the jurisdiction of the com-
mittee concerned 
RESOLUTION 
Commending the progress made by anti-tuberculosis 
programs. 
Whereas tuberculosis (TB) is the second leading fatal global 
infectious disease behind HIV/AIDS, claiming 1,400,000 
lives each year; 
Whereas the global TB pandemic and the spread of drug re-
sistant TB present a persistent public health threat to 
the United States; 
Whereas according to 2010 data of the World Health Organi-
zation, over 7 percent of all new TB cases are drug re-
sistant; 
VerDate Mar 15 2010 
01:22 Mar 23, 2012
Jkt 019200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR594.IH
HR594
tjames on DSK6SPTVN1PROD with BILLS
•HRES 594 IH 
Whereas TB is the leading killer of people with HIV/AIDS 
in the developing world; 
Whereas TB is an under-recognized problem in children that 
can have devastating long-term health effects including 
deafness, blindness, and paralysis, even after cure; 
Whereas TB is the third leading killer of adult women, and 
the stigma associated with TB disproportionately affects 
women, causing them to delay seeking care and inter-
fering with treatment adherence; 
Whereas the Institute of Medicine (IOM) found that the re-
surgence of TB in the United States between 1985 and 
1992 was caused by cuts in TB control funding and the 
spread of HIV/AIDS; 
Whereas although the numbers of TB cases in the United 
States continue to decline, progress towards TB elimi-
nation has slowed, and it is a disease that does not recog-
nize borders; 
Whereas New York City had to spend over $1,000,000,000 
to control a multi-drug resistant TB outbreak between 
1989 and 1993; 
Whereas a new strain of drug resistant TB, known as XDR– 
TB, has emerged that is resistant to all TB drugs and 
has high and rapid fatality rates; 
Whereas the United States has had more than 28 cases of 
XDR–TB over the last decade; 
Whereas the Centers for Disease Control and Prevention esti-
mated in 2009 that it costs $483,000 to treat a single 
case of XDR–TB; 
Whereas African-Americans are 8 times more likely to have 
TB than Caucasians, and significant disparities exist 
VerDate Mar 15 2010 
01:22 Mar 23, 2012
Jkt 019200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR594.IH
HR594
tjames on DSK6SPTVN1PROD with BILLS
•HRES 594 IH 
among other United States minorities, including Native 
Americans, Asian Americans, and Hispanic Americans; 
Whereas although drugs, diagnostics, and vaccines for TB 
exist, these technologies are antiquated and are increas-
ingly inadequate for controlling the global epidemic; 
Whereas there have been no new TB drugs introduced in over 
40 years; 
Whereas current tests to detect drug resistance take at least 
a month to complete and faster drug susceptibility tests 
must be developed to stop the spread of drug resistant 
TB; 
Whereas the TB vaccine, BCG, provides some protection to 
children, but has little or no efficacy in preventing pul-
monary TB in adults; 
Whereas there is also a critical need for new TB drugs that 
can safely be taken concurrently with antiretroviral ther-
apy for HIV; 
Whereas enactment of the Tom Lantos and Henry J. Hyde 
United States Global Leadership Against HIV/AIDS, Tu-
berculosis, and Malaria Reauthorization Act of 2008 and 
the Comprehensive TB Elimination Act provided a his-
toric United States commitment to the global eradication 
of TB, including to the successful treatment of 4,500,000 
new TB patients and 90,000 new multi-drug resistant 
MDR–TB cases by 2013, while providing additional 
treatment through coordinated multilateral efforts; 
Whereas the United States Agency for International Develop-
ment provides financial and technical assistance to nearly 
40 highly burdened TB countries and supports the devel-
opment of new diagnostic and treatment tools, and is au-
VerDate Mar 15 2010 
01:22 Mar 23, 2012
Jkt 019200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6300
E:\BILLS\HR594.IH
HR594
tjames on DSK6SPTVN1PROD with BILLS
•HRES 594 IH 
thorized to support research to develop new vaccines to 
combat TB; 
Whereas the Centers for Disease Control and Prevention, 
working in partnership with States and territories of the 
United States, directs the national TB elimination pro-
gram and essential national TB surveillance, technical as-
sistance, and prevention activities and supports the devel-
opment of new diagnostic, treatment, and prevention 
tools to combat TB; 
Whereas the National Institutes of Health, through its many 
institutes and centers, plays the leading role in basic and 
clinical research into the identification, treatment, and 
prevention of TB; 
Whereas the Global Fund to Fight AIDS, Tuberculosis, and 
Malaria provides over two-thirds of all international fi-
nancing for TB programs worldwide and has supported 
the detection and treatment of 8,600,000 cases of TB; 
Whereas nearly half of the total number of lives saved by the 
Global Fund to Fight AIDS, Tuberculosis, and Malaria 
have been saved through its support for TB programs; 
and 
Whereas March 24, 2012, is World Tuberculosis Day, a day 
that commemorates the date in 1882 when Dr. Robert 
Koch announced his discovery of Mycobacterium tuber-
culosis, the bacteria that causes tuberculosis: Now, there-
fore, be it 
Resolved, That the House of Representatives— 
(1) supports the goals of World TB Day to 
raise awareness about tuberculosis; 
VerDate Mar 15 2010 
01:22 Mar 23, 2012
Jkt 019200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\HR594.IH
HR594
tjames on DSK6SPTVN1PROD with BILLS
•HRES 594 IH 
(2) commends the progress made by United 
States-led anti-tuberculosis programs; and 
(3) reaffirms its commitment to global tuber-
culosis control made through the Tom Lantos and 
Henry J. Hyde United States Global Leadership 
Against HIV/AIDS, Tuberculosis, and Malaria Re-
authorization Act of 2008. 
Æ 
VerDate Mar 15 2010 
01:22 Mar 23, 2012
Jkt 019200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\HR594.IH
HR594
tjames on DSK6SPTVN1PROD with BILLS